Straightforward guidance about neurological symptoms, conditions, diagnostic testing, and treatment—written to help patients and families feel better prepared for what comes next.
A patient-friendly 2026 roundup of major neurology FDA approvals and decisions across Alzheimer’s, Parkinson’s, MS, epilepsy, neuropathy, and sleep apnea.
Botox is FDA-approved for chronic migraine (15+ headache days/month). A Maryland neurologist explains how the injections work and whether insurance covers them.
FDA-approved at-home neurostimulation and TMS devices now treat migraine without daily medication. A Maryland neurologist explains how they work and who they suit.
Northwestern researchers report an FDA-approved compound showed neuroprotective effects in Parkinson’s models. Here’s what this early science could mean.
Tavapadon is an investigational once-daily Parkinson’s pill with an expected 2026 FDA decision. Learn how this D1/D5 agonist differs and what it could mean.
AXS-05 (Auvelity) is FDA-approved for Alzheimer’s disease agitation. A caregiver’s guide to what agitation looks like, why it matters, and current treatment options.
If one of these articles sounds familiar, our team can help you move from symptoms and questions to testing, diagnosis, and follow-up treatment.
11110 Medical Campus Rd Unit 151, Hagerstown, MD 21742
924 Seton Dr Suite C, Cumberland, MD 21502
(301) 797-7600
Secure online messaging, records, and follow-up access for existing patients.